Skip to main content
Top
Published in: BMC Infectious Diseases 1/2012

Open Access 01-12-2012 | Research article

Characteristics of multidrug-resistant tuberculosis in Namibia

Authors: Philip M Ricks, Farai Mavhunga, Surbhi Modi, Rosalia Indongo, Abbas Zezai, Lauren A Lambert, Nick DeLuca, Jamie S Krashin, Allyn K Nakashima, Timothy H Holtz

Published in: BMC Infectious Diseases | Issue 1/2012

Login to get access

Abstract

Background

To describe the epidemiology and possible risk factors for the development of multidrug-resistant tuberculosis (MDR-TB) in Namibia.

Methods

Using medical records and patient questionnaires, we conducted a case-control study among patients diagnosed with TB between January 2007 and March 2009. Cases were defined as patients with laboratory-confirmed MDR-TB; controls had laboratory-confirmed drug-susceptible TB or were being treated with WHO Category I or Category II treatment regimens.

Results

We enrolled 117 MDR-TB cases and 251 TB controls, of which 100% and 2% were laboratory-confirmed, respectively. Among cases, 97% (113/117) had been treated for TB before the current episode compared with 46% (115/251) of controls (odds ratio [OR] 28.7, 95% confidence interval [CI] 10.3–80.5). Cases were significantly more likely to have been previously hospitalized (OR 1.9, 95% CI 1.1–3.5) and to have had a household member with MDR-TB (OR 5.1, 95% CI 2.1–12.5). These associations remained significant when separately controlled for being currently hospitalized or HIV-infection.

Conclusions

MDR-TB was associated with previous treatment for TB, previous hospitalization, and having had a household member with MDR-TB, suggesting that TB control practices have been inadequate. Strengthening basic TB control practices, including expanding laboratory confirmation, directly observed therapy, and infection control, are critical to the prevention of MDR-TB.
Literature
1.
go back to reference Migliori GB, Dheda K, Centis R, Mwaba P, Bates M, et al: Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-saharan africa. Trop Med Int Health. 2010, 15: 1052-1066. 10.1111/j.1365-3156.2010.02581.x.CrossRefPubMed Migliori GB, Dheda K, Centis R, Mwaba P, Bates M, et al: Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-saharan africa. Trop Med Int Health. 2010, 15: 1052-1066. 10.1111/j.1365-3156.2010.02581.x.CrossRefPubMed
2.
go back to reference World Health Organization: Guidelines for the programmatic management of drug-resistant tuberculosis. 2008, Geneva, Switzerland: WHO World Health Organization: Guidelines for the programmatic management of drug-resistant tuberculosis. 2008, Geneva, Switzerland: WHO
3.
go back to reference Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, et al: HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010, 181: 80-86. 10.1164/rccm.200907-0989OC.CrossRefPubMed Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, et al: HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010, 181: 80-86. 10.1164/rccm.200907-0989OC.CrossRefPubMed
4.
go back to reference Wells C, Cegielski JP, Nelson L, Laserson K, Holtz T, et al: HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis. 2007, 196 (Suppl 1): S86-107.CrossRefPubMed Wells C, Cegielski JP, Nelson L, Laserson K, Holtz T, et al: HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis. 2007, 196 (Suppl 1): S86-107.CrossRefPubMed
5.
go back to reference World Health Organization: Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. 2010, Geneva, Switzerland: WHO World Health Organization: Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. 2010, Geneva, Switzerland: WHO
6.
go back to reference Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG: Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis. 2002, 185: 1197-2002. 10.1086/339818.CrossRefPubMed Dye C, Espinal MA, Watt CJ, Mbiaga C, Williams BG: Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis. 2002, 185: 1197-2002. 10.1086/339818.CrossRefPubMed
7.
go back to reference Zignol M, Hosseini M, Wright A, Weezenbeek C, Nunn P, et al: Global incidence of multidrug-resistant tuberculosis. J Infect Dis. 2006, 194: 479-485. 10.1086/505877.CrossRefPubMed Zignol M, Hosseini M, Wright A, Weezenbeek C, Nunn P, et al: Global incidence of multidrug-resistant tuberculosis. J Infect Dis. 2006, 194: 479-485. 10.1086/505877.CrossRefPubMed
8.
go back to reference Andrews JR, Gandhi NR, Moodley P, Shah NS, Bohlken L, et al: Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural south africa. J Infect Dis. 2008, 198: 1582-1589. 10.1086/592991.CrossRefPubMed Andrews JR, Gandhi NR, Moodley P, Shah NS, Bohlken L, et al: Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural south africa. J Infect Dis. 2008, 198: 1582-1589. 10.1086/592991.CrossRefPubMed
9.
go back to reference Ben Amor Y, Nemser B, Singh A, Sankin A, Schluger N: Underreported threat of multidrug-resistant tuberculosis in africa. Emerg Infect Dis. 2008, 14: 1345-1352. 10.3201/eid1409.061524.CrossRefPubMedPubMedCentral Ben Amor Y, Nemser B, Singh A, Sankin A, Schluger N: Underreported threat of multidrug-resistant tuberculosis in africa. Emerg Infect Dis. 2008, 14: 1345-1352. 10.3201/eid1409.061524.CrossRefPubMedPubMedCentral
10.
go back to reference Gandhi N, Moll A, Sturm A, Pawinski R, Govender T, et al: Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of south africa. Lancet. 2006, 368: 1575-1580. 10.1016/S0140-6736(06)69573-1.CrossRefPubMed Gandhi N, Moll A, Sturm A, Pawinski R, Govender T, et al: Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of south africa. Lancet. 2006, 368: 1575-1580. 10.1016/S0140-6736(06)69573-1.CrossRefPubMed
11.
go back to reference van Rie A, Warren R, Beyers N, Gie R, Classen C, et al: Transmission of a multidrug-resistant mycobacterium tuberculosis strain resembling ″strain W″ among noninstitutionalized, human immunodeficiency virus-seronegative patients. J Infect Dis. 1999, 180: 1608-1615. 10.1086/315054.CrossRefPubMed van Rie A, Warren R, Beyers N, Gie R, Classen C, et al: Transmission of a multidrug-resistant mycobacterium tuberculosis strain resembling ″strain W″ among noninstitutionalized, human immunodeficiency virus-seronegative patients. J Infect Dis. 1999, 180: 1608-1615. 10.1086/315054.CrossRefPubMed
12.
go back to reference Victor T, Streicher E, Kewley C, Jordaan A, van der Spuy G, et al: Spread of an emerging mycobacterium tuberculosis drug-resistant strain in the western cape of south africa. Int J Tuberc Lung Dis. 2007, 11: 195-201.PubMed Victor T, Streicher E, Kewley C, Jordaan A, van der Spuy G, et al: Spread of an emerging mycobacterium tuberculosis drug-resistant strain in the western cape of south africa. Int J Tuberc Lung Dis. 2007, 11: 195-201.PubMed
13.
go back to reference Diande S, Sangare L, Kouanda S, Dingtoumda BI, Mourfou A, et al: Risk factors for multidrug-resistant tuberculosis in four centers in burkina faso, west africa. Microb Drug Resist. 2009, 15: 217-221. 10.1089/mdr.2009.0906.CrossRefPubMed Diande S, Sangare L, Kouanda S, Dingtoumda BI, Mourfou A, et al: Risk factors for multidrug-resistant tuberculosis in four centers in burkina faso, west africa. Microb Drug Resist. 2009, 15: 217-221. 10.1089/mdr.2009.0906.CrossRefPubMed
14.
go back to reference Faustini A, Hall AJ, Perucci CA: Risk factors for multidrug resistant tuberculosis in europe: a systematic review. Thorax. 2006, 61: 158-163. 10.1136/thx.2005.045963.CrossRefPubMed Faustini A, Hall AJ, Perucci CA: Risk factors for multidrug resistant tuberculosis in europe: a systematic review. Thorax. 2006, 61: 158-163. 10.1136/thx.2005.045963.CrossRefPubMed
15.
go back to reference Temple B, Ayakaka I, Ogwang S, Nabanjja H, Kayes S, et al: Rate and amplification of drug resistance among previously-treated patients with tuberculosis in kampala, uganda. Clin Infect Dis. 2008, 47: 1126-1134. 10.1086/592252.CrossRefPubMedPubMedCentral Temple B, Ayakaka I, Ogwang S, Nabanjja H, Kayes S, et al: Rate and amplification of drug resistance among previously-treated patients with tuberculosis in kampala, uganda. Clin Infect Dis. 2008, 47: 1126-1134. 10.1086/592252.CrossRefPubMedPubMedCentral
16.
go back to reference Ministry of Health and Social Services: Revised Guidelines on the Management of Multi-Drug Resistant (MDR), Polyresistant (PR) Tuberculosis and Mycobacterium Other then Tuberculosis (MOTT). 2008, MOHSS: Republic of Namibia Ministry of Health and Social Services: Revised Guidelines on the Management of Multi-Drug Resistant (MDR), Polyresistant (PR) Tuberculosis and Mycobacterium Other then Tuberculosis (MOTT). 2008, MOHSS: Republic of Namibia
17.
go back to reference Ministry of Health and Social Services: National Tuberculosis and Leprosy Control Programme 2008/2009 Annual Report. 2010, MOHSS: Republic of Namibia Ministry of Health and Social Services: National Tuberculosis and Leprosy Control Programme 2008/2009 Annual Report. 2010, MOHSS: Republic of Namibia
18.
go back to reference Ministry of Health and Social Services: National Guidelines for Management of Tuberculosis. 2006, MOHSS: Republic of Namibia Ministry of Health and Social Services: National Guidelines for Management of Tuberculosis. 2006, MOHSS: Republic of Namibia
19.
go back to reference World Health Organization: Tuberculosis Treatment: Guidelines for National Programmes. 2003, Geneva, Switzerland: WHO World Health Organization: Tuberculosis Treatment: Guidelines for National Programmes. 2003, Geneva, Switzerland: WHO
20.
go back to reference Ministry of Health and Social Services: Tuberculosis Infection Control Guidelines. 2008, MOHSS: Republic of Namibia Ministry of Health and Social Services: Tuberculosis Infection Control Guidelines. 2008, MOHSS: Republic of Namibia
21.
go back to reference Galgalo T, Dalal S, Cain KP, Oeltmann J, Tetteh C, et al: Tuberculosis risk among staff of a large public hospital in kenya. Int J Tuberc Lung Dis. 2008, 12: 949-954.PubMed Galgalo T, Dalal S, Cain KP, Oeltmann J, Tetteh C, et al: Tuberculosis risk among staff of a large public hospital in kenya. Int J Tuberc Lung Dis. 2008, 12: 949-954.PubMed
22.
go back to reference Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, et al: Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in latvia: a retrospective cohort study. Lancet. 2005, 365: 318-326.CrossRefPubMed Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, et al: Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in latvia: a retrospective cohort study. Lancet. 2005, 365: 318-326.CrossRefPubMed
23.
go back to reference Ministry of Health and Social Services: Directorate of Special Programs: National Guidelines for Antiretroviral Therapy: Second Edition. 2007, MOHSS: Republic of Namibia Ministry of Health and Social Services: Directorate of Special Programs: National Guidelines for Antiretroviral Therapy: Second Edition. 2007, MOHSS: Republic of Namibia
24.
go back to reference Casal M, Vaquero M, Rinder H, Tortoli J, Grosset J, et al: A case-control study for multidrug-resistant tuberculosis: risk factors in four european countries. Microb Drug Resist. 2005, 11: 62-67. 10.1089/mdr.2005.11.62.CrossRefPubMed Casal M, Vaquero M, Rinder H, Tortoli J, Grosset J, et al: A case-control study for multidrug-resistant tuberculosis: risk factors in four european countries. Microb Drug Resist. 2005, 11: 62-67. 10.1089/mdr.2005.11.62.CrossRefPubMed
25.
go back to reference Weyer K, Brand J, Lancaster J, Levin J, van der Walt M: Determinants of multidrug-resistant tuberculosis in south africa: results from a national survey. South African Medical Journal. 2007, 97: 1120-1128.PubMed Weyer K, Brand J, Lancaster J, Levin J, van der Walt M: Determinants of multidrug-resistant tuberculosis in south africa: results from a national survey. South African Medical Journal. 2007, 97: 1120-1128.PubMed
26.
go back to reference World Health Organization: Guidelines for tuberculosis treatment in adults and children in national tuberculosis programmes. 1991, Geneva, Switzerland: WHO World Health Organization: Guidelines for tuberculosis treatment in adults and children in national tuberculosis programmes. 1991, Geneva, Switzerland: WHO
27.
go back to reference Adatu F, Odeke R, Mugenyi M, Gargioni G, McCray E, et al: Implementation of the DOTS strategy for tuberculosis control in rural kiboga district, uganda, offering patients the option of treatment supervision in the community, 1998-1999. Int J Tuberc Lung Dis. 2003, 7: S63-S71.PubMed Adatu F, Odeke R, Mugenyi M, Gargioni G, McCray E, et al: Implementation of the DOTS strategy for tuberculosis control in rural kiboga district, uganda, offering patients the option of treatment supervision in the community, 1998-1999. Int J Tuberc Lung Dis. 2003, 7: S63-S71.PubMed
28.
go back to reference Dheda K, Shean K, Zumla A, Badri M, Streicher EM, et al: Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in south africa: a retrospective cohort study. Lancet. 2010, 375: 1798-1807. 10.1016/S0140-6736(10)60492-8.CrossRefPubMed Dheda K, Shean K, Zumla A, Badri M, Streicher EM, et al: Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in south africa: a retrospective cohort study. Lancet. 2010, 375: 1798-1807. 10.1016/S0140-6736(10)60492-8.CrossRefPubMed
29.
go back to reference Ministry of Health and Social Services: Report of an External Review: National Tuberculosis and Leprosy Control Programme Medium Term Plan (MTP 1). 2009, Republic of Namibia: MOHSS Ministry of Health and Social Services: Report of an External Review: National Tuberculosis and Leprosy Control Programme Medium Term Plan (MTP 1). 2009, Republic of Namibia: MOHSS
30.
go back to reference World Health Organization: Global tuberculosis control - epidemiology, strategy, financing: WHO Report 2009. 2009, Geneva, Switzerland: WHO World Health Organization: Global tuberculosis control - epidemiology, strategy, financing: WHO Report 2009. 2009, Geneva, Switzerland: WHO
31.
go back to reference World Health Organization: WHO Policy on TB infection control in health-care facilities, congregate settings and households. 2009, Geneva, Switzerland: WHO World Health Organization: WHO Policy on TB infection control in health-care facilities, congregate settings and households. 2009, Geneva, Switzerland: WHO
32.
go back to reference Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G: Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in south africa. J Infect Dis. 2007, 196 (Suppl 3): S482-490.CrossRefPubMed Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G: Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in south africa. J Infect Dis. 2007, 196 (Suppl 3): S482-490.CrossRefPubMed
33.
go back to reference Suchindran S, Brouwer ES, Van Rie A: Is HIV infection a risk factor for multi-drug resistant tuberculosis? a systematic review. PLoS One. 2009, 4: e5561-10.1371/journal.pone.0005561.CrossRefPubMedPubMedCentral Suchindran S, Brouwer ES, Van Rie A: Is HIV infection a risk factor for multi-drug resistant tuberculosis? a systematic review. PLoS One. 2009, 4: e5561-10.1371/journal.pone.0005561.CrossRefPubMedPubMedCentral
34.
go back to reference Braun MM, Kilburn JO, Smithwick RW, Coulibaly IM, Coulibaly D, et al: HIV infection and primary resistance to antituberculosis drugs in abidjan, cote d′Ivoire. AIDS. 1992, 6: 1327-1330. 10.1097/00002030-199211000-00014.CrossRefPubMed Braun MM, Kilburn JO, Smithwick RW, Coulibaly IM, Coulibaly D, et al: HIV infection and primary resistance to antituberculosis drugs in abidjan, cote d′Ivoire. AIDS. 1992, 6: 1327-1330. 10.1097/00002030-199211000-00014.CrossRefPubMed
35.
go back to reference Brust JC, Gandhi NR, Carrara H, Osburn G, Padayatchi N: High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-natal, south africa, 2000-2003. Int J Tuberc Lung Dis. 2010, 14: 413-419.PubMedPubMedCentral Brust JC, Gandhi NR, Carrara H, Osburn G, Padayatchi N: High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-natal, south africa, 2000-2003. Int J Tuberc Lung Dis. 2010, 14: 413-419.PubMedPubMedCentral
36.
go back to reference Chum HJ, O′Brien RJ, Chonde TM, Graf P, Rieder HL: An epidemiological study of tuberculosis and HIV infection in tanzania, 1991-1993. AIDS. 1996, 10: 299-309. 10.1097/00002030-199603000-00009.CrossRefPubMed Chum HJ, O′Brien RJ, Chonde TM, Graf P, Rieder HL: An epidemiological study of tuberculosis and HIV infection in tanzania, 1991-1993. AIDS. 1996, 10: 299-309. 10.1097/00002030-199603000-00009.CrossRefPubMed
37.
go back to reference Githui W, Nunn P, Juma E, Karimi F, Brindle R, et al: Cohort study of HIV-positive and HIV-negative tuberculosis, nairobi, kenya: comparison of bacteriological results. Tuber Lung Dis. 1992, 73: 203-209. 10.1016/0962-8479(92)90087-Z.CrossRefPubMed Githui W, Nunn P, Juma E, Karimi F, Brindle R, et al: Cohort study of HIV-positive and HIV-negative tuberculosis, nairobi, kenya: comparison of bacteriological results. Tuber Lung Dis. 1992, 73: 203-209. 10.1016/0962-8479(92)90087-Z.CrossRefPubMed
38.
go back to reference Patel KB, Belmonte R, Crowe HM: Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med. 1995, 332: 336-337.CrossRefPubMed Patel KB, Belmonte R, Crowe HM: Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med. 1995, 332: 336-337.CrossRefPubMed
39.
go back to reference Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, et al: HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010, 181: 80-86. 10.1164/rccm.200907-0989OC.CrossRefPubMed Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, et al: HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010, 181: 80-86. 10.1164/rccm.200907-0989OC.CrossRefPubMed
40.
go back to reference World Health Organization: Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2010 revision. 2010, Geneva, Switzerland: WHO World Health Organization: Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2010 revision. 2010, Geneva, Switzerland: WHO
Metadata
Title
Characteristics of multidrug-resistant tuberculosis in Namibia
Authors
Philip M Ricks
Farai Mavhunga
Surbhi Modi
Rosalia Indongo
Abbas Zezai
Lauren A Lambert
Nick DeLuca
Jamie S Krashin
Allyn K Nakashima
Timothy H Holtz
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2012
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-12-385

Other articles of this Issue 1/2012

BMC Infectious Diseases 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine